NCT02197520View on ClinicalTrials.gov

A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Insulin Peglispro

Administered subcutaneously (SC), (U-100 formulation)

DRUG

Insulin Glargine

Administered subcutaneously (SC), (U-100 formulation)

DRUG

Insulin Lispro

Administered subcutaneously (SC), (U-100 formulation)

Trial Locations (1)

91911

Profil Institute for Clinical Research Inc, Chula Vista

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT02197520 - A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics | Biotech Hunter | Biotech Hunter